<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01910610</url>
  </required_header>
  <id_info>
    <org_study_id>STRATEGIC-1 C12- 2</org_study_id>
    <secondary_id>2013-001928-19</secondary_id>
    <nct_id>NCT01910610</nct_id>
  </id_info>
  <brief_title>Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer</brief_title>
  <acronym>STRATEGIC-1</acronym>
  <official_title>Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with
      metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with
      unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are
      being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab,
      cetuximab or panitumumab) but in a different order:

      STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
      vs.

      STRATEGY B: OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab,
      followed by anti-EGFR mab with or without irinotecan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Disease Control</measure>
    <time_frame>From baseline until end of strategy, assessed up to 80 months after the beginning of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>from baseline until end of strategy, assessed up to 80 months after the beginning of the study</time_frame>
    <description>QoL will be considered to be improved if at least one time to QoL score deterioration (Five targeted dimensions) will be significantly longer without a significant shorter time to QoL score dimensions for other 4 targeted dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>time interval from randomization to the date of death from any cause. Assessed up to 80 months after the beginning of the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Failure of Strategy</measure>
    <time_frame>Assessed up to 80 months after the beginning of the study</time_frame>
    <description>TFS is defined as beginning with the initiation of the strategy under investigation and ending with the first of the following events: 1) death, 2) disease progression on the last received planned sequence, 3) patient requires the addition of a new (unplanned) therapeutic agent, 4) patient experiences disease progression during a partial or complete break in therapy from initial treatment strategy and receives no further therapy within one month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) per sequence of therapy</measure>
    <time_frame>the time interval from randomization to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed up to 80 months after the beginning of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response Rate (RR)</measure>
    <time_frame>from baseline until end of strategy, assessed up to 80 months after the beginning of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Curative salvage surgery rate</measure>
    <time_frame>from baseline until end of strategy, assessed up to 80 months after the beginning of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of each treatment sequence</measure>
    <time_frame>Assessed from study entry to 1 month after last study drug administration, assessed up to 80 months after the beginning of the study</time_frame>
    <description>The study will take into account all adverse events observed during and after drug administration, with a particular interest for:
Any AE Any serious AE Any serious AE related to study treatment Any NCI-CTC grade 3 or 4 AE Any AE causing discontinuation of study treatment Any AE causing a dose reduction of study medication Any AE leading to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">474</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>STRATEGY A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STRATEGY B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FOLFIRI-cetuximab</intervention_name>
    <arm_group_label>STRATEGY A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mFOLFOX6-bevacizumab</intervention_name>
    <arm_group_label>STRATEGY A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPTIMOX-bevacizumab</intervention_name>
    <arm_group_label>STRATEGY B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>irinotecan-based chemo + bevacizumab</intervention_name>
    <arm_group_label>STRATEGY B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)</intervention_name>
    <arm_group_label>STRATEGY B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XELOX + bevacizumab</intervention_name>
    <arm_group_label>STRATEGY A</arm_group_label>
    <arm_group_label>STRATEGY B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent, and willing and able to comply with protocol
             requirements,

          2. Histologically proven adenocarcinoma of the colon and/or rectum,

          3. Wild-type RAS tumor no mutation in exon 2 [codon 12/13], exon 3 [codon 59/61] and exon
             4 [codon 117/146] of both KRAS and NRAS genes (local assessment, performed either on
             primary tumor or metastasis), In exceptional circumstances, RAS mutational status
             (KRAS and NRAS) can be pending at time of randomization, provided it is obtained
             within the first two cycles of first line therapy

          4. Metastatic disease confirmed,

          5. No prior therapy for metastatic disease (in case of previous adjuvant therapy,
             interval from end of chemotherapy and relapse must be &gt;6 months for fluoropyrimidine
             alone or &gt;12 months for oxaliplatin-based, bevacizumab-based, or cetuximab-based
             therapy),

          6. Duly documented unresectable metastatic disease, ie not suitable for complete
             carcinological surgical resection at inclusion [NB: patients with unresectable disease
             at study entry but with any potential of salvage surgery after induction therapy are
             eligible],

          7. At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic
             Resonance Imaging) according to RECIST v1.1,

          8. Age ≥18 years,

          9. ECOG Performance status (PS) 0-2,

         10. Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; haemoglobin
             ≥9g/dL,

         11. Adequate renal function: serum creatinine level &lt;150µM,

         12. Adequate liver function: serum bilirubin ≤1.5 x upper normal limit (ULN), alkaline
             phosphatase &lt;5xULN,

         13. Proteinuria &lt;2+ (dipstick urinalysis) or ≤1g/24hour,

         14. Baseline evaluations performed before randomization when the KRAS WT status is known:
             clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization,
             tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than 3
             weeks (21 days) prior to randomization,

         15. Female patients must commit to using reliable and appropriate methods of contraception
             during the trial and until at least six months after the end of study treatment (when
             applicable). Male patients with a partner of childbearing potential must agree to use
             contraception in addition to having their partner use another contraceptive method
             during the trial and until at least 6 months after the end of the study treatment,

         16. Registration in a national health care system (CMU included for France).

        Exclusion Criteria:

          1. History or evidence upon physical examination of CNS metastasis (e.g. non irradiated
             CNS metastasis, seizure not controlled with standard medical therapy), unless
             adequately treated,

          2. Exclusive bone metastasis,

          3. Uncontrolled hypercalcemia,

          4. Pre-existing permanent neuropathy (NCI grade ≥2),

          5. Uncontrolled hypertension (defined as systolic blood pressure &gt;150 mmHg and/or
             diastolic blood pressure &gt;100 mmHg), or history of hypertensive crisis, or
             hypertensive encephalopathy,

          6. Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted
             therapy, immunotherapy),

          7. Treatment with any investigational medicinal product within 28 days prior to study
             entry,

          8. Other serious and uncontrolled non-malignant disease,

          9. Gilbert's syndrome,

         10. Other concomitant or previous malignancy, except: i/ adequately treated in-situ
             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,
             iii/ cancer in complete remission for &gt;5 years,

         11. Major surgery (open biopsy, surgical resection, wound revision or any other major
             surgery involving entry into body cavity) or significant traumatic injury within the
             last 28 days prior to randomization, and/or minor surgical procedure including
             placement of a vascular device within 2 days of first study treatment,

         12. Pregnant or breastfeeding women,

         13. Patients with known allergy/hypersensitivity to any component of study drugs,

         14. History of arterial thrombo and/or embolic event (e.g. myocardial infarction,
             stroke,…) within 6 months prior to randomization,

         15. Chronic inflammatory bowel disease

         16. Total bowel obstruction,

         17. History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI
             bleeding within 6 months prior to randomization,

         18. Serious, non-healing wound, active ulcer or untreated bone fracture,

         19. History or evidence of inherited bleeding diathesis or significant coagulopathy at
             risk of bleeding,

         20. Current or recent (within 10 days of randomization) use of aspirin (&gt;325 mg/d),
             clopidogrel (&gt;75 mg/d) or use of oral anticoagulants or thrombolytic agents.

         21. Concomitant administration of live, attenuated virus vaccine such as yellow fever
             vaccine

         22. Concomitant administration of prophylactic phenytoin.

         23. Treatment with sorivudine or its chemically related analogues, such as brivudine.

         24. Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.

         25. Concomitant use with St John's Wort

         26. Patients with interstitial pneumonitis or pulmonary fibrosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoist Chibaudel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Hospitalier Franco-Britannique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoist Chibaudel, MD</last_name>
    <phone>+33(0)1 47 59 19 23</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Gennevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MAILLARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuel MAILLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Auxerre</name>
      <address>
        <city>Auxerre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Laure VILLING, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Laure VILLING, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélie PARZY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie PARZY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence SAUDES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence SAUDES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Chateauroux</name>
      <address>
        <city>Chateauroux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François CHRISTIANN, MD</last_name>
    </contact>
    <investigator>
      <last_name>François CHRISTIANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles BREYSACHER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles BREYSACHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe TOURNIGAND, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe TOURNIGAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Dax</city>
        <zip>40107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence GAUTHIER-FELIZOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence GAUTHIER-FELIZOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie et de radiothérapie du Parc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève JOLIMOY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Geneviève JOLIMOY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GHIRINGHELLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>François GHIRINGHELLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger FAROUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roger FAROUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pasteur</name>
      <address>
        <city>Le Coudray</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela TOSSEN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gabriela TOSSEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé de l'Estuaire</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel MORAN RIBON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Angel MORAN RIBON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier DUPUIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier DUPUIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut d'oncoloige Hartmann</name>
      <address>
        <city>Levallois Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Michel VANNETZEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Michel VANNETZEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique</name>
      <address>
        <city>Levallois Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoist CHIBAUDEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoist CHIBAUDEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Bourgogne</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MARTIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe MARTIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joëlle EGRETEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joëlle EGRETEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme DESRAME, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme DESRAME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves RINALDI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yves RINALDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed GASMI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mohamed GASMI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Layné</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme DAUBA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme DAUBA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien BROCARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabien BROCARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Sainte Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François RAMEE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-François RAMEE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain CORIAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Romain CORIAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste BACHET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Baptiste BACHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierrry ANDRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry ANDRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaël DEPLANQUE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gaël DEPLANQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc GORNET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Marc GORNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed KHALIL, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ahmed KHALIL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LOUVET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe LOUVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Périgueux</name>
      <address>
        <city>Périgueux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edgard MOITSINGA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Edgard MOITSINGA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Alliance</name>
      <address>
        <city>Saint Cyr sur Loire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claude BIELSA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claude BIELSA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Broussais - CH Saint Malo</name>
      <address>
        <city>Saint Malo</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain DESGRIPPES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Romain DESGRIPPES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léa SABAN ROCHE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Léa SABAN ROCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Luc ETIENNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Luc ETIENNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Senlis</name>
      <address>
        <city>Senlis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Elisabeth CAROLA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth CAROLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Sens</name>
      <address>
        <city>Sens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure CHAUVENET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laure CHAUVENET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Anne</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Marie DOURTHE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Louis-Marie DOURTHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>May MABRO, MD</last_name>
    </contact>
    <investigator>
      <last_name>May MABRO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du Léman</name>
      <address>
        <city>Thonon Les Bains</city>
        <zip>74200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ahmed BEDJAOUI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric VIRET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric VIRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Générale</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyril BONAVENTURE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cyril BONAVENTURE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie</name>
      <address>
        <city>Villeneuve-d'Ascq</city>
        <zip>59657</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier ROMANO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adelaide &amp; Meath Hospital Dublin ( AMNCH)</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Ireland</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wild-type RAS metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

